- Midatech Pharma (NASDAQ:MTP) rallies premarket after announcing positive results from a Phase I study evaluating MTX110, an investigational nano-inclusion product, for the treatment of the fatal childhood brain cancer in patients with diffuse intrinsic pontine glioma (DPIG).
- At interim data cutoff, median overall survival (OS) was 26.1 months. OS at month 12 was 71.4% (n=5/7).
- The primary endpoint of the planned 19-subject Phase 2 trial will be OS at month 12. MTX110 will be delivered using an alternative CED catheter system that enables regular drug infusions directly into the tumor without a need for repeated surgery.
- https://seekingalpha.com/news/3623128-midatechs-mtx110-shows-survival-benefit-in-rare-pediatric-brain-cancer-study-shares-up-37
Monday, October 19, 2020
Midatech's MTX110 shows survival benefit in rare pediatric brain cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.